SCHEMBL2300296

SCHEMBL2300296

O=S(=O)(Cl)Cl.O=S(=O)(c1ccccc1)N1CCCC1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.73
LMNA P02545 2/20 0.73
GAA P10253 2/20 0.70
USP2 O75604 1/20 0.67
TSHR P16473 2/20 0.64
THRB P10828 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
APOBEC3A P31941 1/20 0.62
APOBEC3G Q9HC16 1/20 0.62
POLB P06746 1/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
KDM4E B2RXH2 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.59
PKM P14618 1/20 0.59
CYP2D6 P10635 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1988224 0.94 ALDH1A1 (0.81) ALDH1A1LMNAGAAUSP2TSHR
SCHEMBL6805741 0.94 ALDH1A1 (0.81) ALDH1A1LMNAGAAUSP2TSHR
SCHEMBL1902263 0.92 ALDH1A1 (0.85) ALDH1A1LMNAGAAUSP2TSHR
SCHEMBL10445162 0.92 ALDH1A1 (0.85) ALDH1A1LMNAGAAUSP2TSHR
SCHEMBL14470279 0.90 ALDH1A1 (0.75) ALDH1A1LMNAGAAUSP2TSHR
SCHEMBL735657 0.85 POLB (0.80) ALDH1A1LMNAGAATSHRAPOBEC3A
SCHEMBL7122592 0.85 POLB (0.80) ALDH1A1LMNAGAATSHRAPOBEC3A
SCHEMBL3830424 0.85 POLB (0.80) ALDH1A1LMNAGAATSHRAPOBEC3A
SCHEMBL3252762 0.83 KMT2A (0.73) ALDH1A1LMNAGAATSHRNPSR1
SCHEMBL5407453 0.82 ALDH1A1 (1.00) ALDH1A1LMNAGAAUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877757-B2 Pyrazine derivatives and use as PI3K inhibitors MERCK SERONO SA (CH) 2014-11-04 US disclosed
CN-101378757-B Thiadiazole derivatives for the treatment of neuro degenerative diseases REMYND NV 2012-08-01 CN disclosed
US-20110319410-A1 PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS MERCK SERONO SA (CH) 2011-12-29 US disclosed
US-20110312960-A1 PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS MERCK SERONO SA (CH) 2011-12-22 US disclosed
US-8071597-B2 Pyrazine compounds and uses as PI3K inhibitors MERCK SERONO SA (CH) 2011-12-06 US disclosed
EP-2351745-A1 Pyrazine derivatives and use as PI3K inhibitors Merck Serono S.A. (CH) 2011-08-03 EP disclosed
US-20090082356-A1 Pyrazine Derivatives and Use as P13k Inhibitors MERCK SERONO SA (CH) 2009-03-26 US disclosed
CN-101378757-A Thiadiazole derivatives for the treatment of neuro degenerative diseases REMYND NV (BE) 2009-03-04 CN disclosed
CN-100356979-C Integrin expression inhibitors EISAI CO LTD (JP) 2007-12-26 CN disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082356-A1 Pyrazine Derivatives and Use as P13k Inhibitors PI4KA, PIP5K1B, PDPK1 ALDH1A1 1531/4885LMNA 3458/4885GAA 4013/4885
US-20110312960-A1 PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS PIK3R5, PIK3CD, PIK3CA ALDH1A1 2357/4885LMNA 4784/4885GAA 4399/4885
US-20110319410-A1 PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS PIK3R5, PIK3CD, PIK3CA ALDH1A1 2357/4885LMNA 4784/4885GAA 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.